Alloy Therapeutics

Alloy Therapeutics describes itself as a Product Development Organization (PDO) that partners with biotech innovators, pharma, academic founders, and sovereign organizations across discovery, preclinical, and clinical development.

Key service areas

• Antibody and multispecific discovery: AI/ML-driven campaigns from design to IND, using in vivo discovery platforms with fully human transgenic models (including hyperimmune mice and common light-chain strains), plus AI/ML clone selection and binding, developability, and functional testing.
• Multispecific engineering and optimization: Integrated discovery, engineering, and screening workflows, and optimization for affinity, specificity, or developability.
• TCR mimics (TCRm): Discovery of antibodies targeting intracellular peptides presented on MHC complexes, via the Keyway platform.
• Genetic medicines: Antisense oligonucleotide design, including refinement of existing sequences or de novo design in the Anticlastic cyclized format, and the Anticlastic Cyclic RNA platform.
• Pharmacology: In vitro and in vivo study design aligned to a program's target product profile, delivered through the Alloy Precision unit.
• Platform access: Broad access to the transgenic discovery platform through the ATX-GX license with flexible business terms.

The company states it has supported partners with 200+ collaborators, 110+ active drug programs declared by partners, and 25 INDs filed since its first platform.